| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues: |
| Dermatology Recurring Procedures | 5.5 | 5.2 | | 5.8 | 5.6 | 5.1 | | 5.7 |
| Dermatology Procedures Equipment | 2.8 | 2.4 | | 3.6 | 3.5 | 2.0 | | 2.0 |
| Total revenues | 8.3 | 7.6 | 10.6 | 9.4 | 9.1 | 7.0 | 9.1 | 7.7 |
| Revenue growth [+] | -9.4% | 7.5% | 17.1% | 22.1% | 23.3% | 20.8% | 34.8% | 37.4% |
| Dermatology Recurring Procedures | -2.3% | 2.8% | | 2.4% | 2.4% | 8.3% | | 48.9% |
| Dermatology Procedures Equipment | -20.7% | 19.5% | | 78.2% | 82.5% | 72.0% | | 12.5% |
| Cost of goods sold | 3.9 | 3.2 | 3.8 | 3.6 | 4.1 | 2.9 | 3.1 | 2.3 |
| Gross profit | 4.3 | 4.4 | 6.8 | 5.8 | 5.0 | 4.1 | 6.0 | 5.4 |
| Gross margin | 52.3% | 58.0% | 64.6% | 61.6% | 54.8% | 58.6% | 66.2% | 69.7% |
| Selling, general and administrative [+] | 5.9 | 6.7 | 6.3 | 6.4 | 6.5 | 6.3 | 6.3 | 5.5 |
| Sales and marketing | 3.4 | 3.7 | 3.8 | 3.8 | 4.1 | 3.6 | 3.7 | 3.3 |
| General and administrative | 2.5 | 2.9 | 2.5 | 2.6 | 2.3 | 2.7 | 2.6 | 2.2 |
| Other selling, general and administrative | | | | | | | | |
| Research and development | 0.4 | 0.3 | 0.4 | 0.2 | 0.2 | 0.2 | 0.3 | 0.4 |
| EBITDA [+] | -0.5 | -1.2 | 1.5 | 0.5 | -0.4 | -1.0 | 1.5 | 0.1 |
| EBITDA growth | 50.4% | 21.1% | -5.3% | 377.3% | -53.0% | -37.0% | 249.5% | -131.1% |
| EBITDA margin | -6.5% | -15.7% | 13.7% | 5.6% | -3.9% | -13.9% | 17.0% | 1.4% |
| Depreciation | 0.0 | 0.7 | 3.5 | 0.6 | -0.1 | 0.6 | 3.3 | 0.2 |
| EBITA | -0.5 | -1.9 | -2.0 | -0.1 | -0.3 | -1.6 | -1.7 | -0.1 |
| EBITA margin | -6.4% | -24.7% | -19.1% | -0.7% | -2.8% | -22.8% | -19.2% | -0.7% |
| Amortization of intangibles | 1.4 | 0.7 | -2.2 | 0.7 | 1.4 | 0.7 | -1.1 | 0.4 |
| EBIT [+] | -2.0 | -2.6 | 0.1 | -0.8 | -1.7 | -2.3 | -0.6 | -0.5 |
| EBIT growth | 15.8% | 12.3% | -121.5% | 69.0% | 83.5% | -3.7% | 76.7% | -59.9% |
| EBIT margin | -23.8% | -34.2% | 1.3% | -8.4% | -18.6% | -32.7% | -6.9% | -6.0% |
| Interest expense, net [+] | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 |
| Interest expense | 0.3 | 0.3 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 |
| Interest income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | 0.0 | 0.0 |
| Other income (expense), net [+] | -0.9 | | | | | | 0.0 | |
| Gain (loss) on debt retirement | -0.9 | | | | | | | |
| Pre-tax income | -3.1 | -2.8 | -0.1 | -1.0 | -1.9 | -2.5 | -0.8 | -0.5 |
| Income taxes | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | | 0.0% | 0.0% | 0.0% | | |
| Net income | -3.1 | -2.8 | -0.2 | -1.0 | -1.9 | -2.5 | -0.8 | -0.5 |
| Net margin | -38.2% | -37.5% | -1.5% | -10.6% | -20.8% | -35.5% | -9.4% | -6.8% |
| |
| Basic EPS [+] | ($0.09) | ($0.08) | $0.00 | ($0.03) | ($0.05) | ($0.07) | ($0.02) | ($0.02) |
| Growth | 65.6% | 12.7% | -81.5% | 87.8% | -270.6% | 0.9% | 89.2% | -58.9% |
| Diluted EPS [+] | ($0.09) | ($0.08) | $0.00 | ($0.03) | ($0.05) | ($0.07) | ($0.02) | ($0.02) |
| Growth | 65.6% | 12.7% | -81.5% | 87.8% | -272.8% | 0.9% | 89.2% | -58.9% |
| |
| Shares outstanding (basic) [+] | 34.9 | 34.9 | 34.7 | 34.7 | 34.7 | 34.7 | 34.1 | 34.2 |
| Growth | 0.5% | 0.5% | 1.9% | 1.7% | 2.5% | 2.6% | 1.3% | 1.2% |
| Shares outstanding (diluted) [+] | 34.9 | 34.9 | 34.7 | 34.7 | 34.7 | 34.7 | 34.1 | 34.2 |
| Growth | 0.5% | 0.5% | 1.9% | 1.7% | 1.2% | 2.6% | 1.3% | 1.2% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |